|
시장보고서
상품코드
2078024
헤모글로빈병증 치료제 시장 : 약제 유형별, 질환 유형별, 유통 채널별, 지역별Hemoglobinopathy Treatment Drugs Market, By Drug Type, By Disease Type, By Distribution Channel, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) |
||||||
헤모글로빈병증 치료제 시장은 2026년에 57억 4,000만 달러, 2033년까지 102억 4,000만 달러에 이를 것으로 예상되고 있습니다. 또한, 2026-2033년 CAGR 8.6%를 기록할 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 57억 4,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 8.60% | 예측 금액(2033년) | 102억 4,000만 달러 |
헤모글로빈 질환이란, 헤모글로빈과 관련된 모든 유전성 질환을 말합니다. 이것들은 주로 살라세미아 증후군과 구조적 헤모글로빈 변이체(비정상 헤모글로빈)의 두 가지 그룹으로 분류됩니다. 사라세미아에는 주로 A형과 B형이 있으며, 주요 구조적 헤모글로빈 변이체로는 HbS, HbE, HbC가 있습니다. 각 그룹에는 많은 아형과 복합형이 존재합니다. 헤모글로빈 질환의 임상 증상은 매우 다양하며, 경도의 저색소성 빈혈부터 중등도의 혈액 질환, 나아가 다기관 손상을 동반하는 중증의 평생 수혈 의존성 빈혈에 이르기까지 광범위합니다. 중증 형태의 살라세미아의 경우, 조혈모세포 이식이 1차 치료법이 됩니다. 근치적 치료라기보다는 대증 요법으로, 평생에 걸쳐 정기적인 수혈과 철 킬레이트 요법을 병행합니다. 겸상적혈구증의 증상을 치료하기 위한 약물로는 진통제, 항생제, ACE 억제제, 하이드록시우레아 등이 있습니다. 수혈은 엄격히 필요하다고 인정되는 경우에만 실시해야 합니다. 현재 환자의 90% 이상이 성인기까지 생존하고 있습니다. 최적의 치료를 받은 환자의 예상 수명은 50-60년입니다. 전 세계 인구의 약 7%가 보균자인 헤모글로빈 질환은 가장 흔한 단일 유전자 질환이며, 전 세계적으로 주요 건강 문제 중 하나입니다. 당초 이러한 질환들은 주로 지중해 지역과 아시아 및 아프리카의 광범위한 지역에서 확인되었습니다. 국제적인 이주를 통해 이 지역들에서 전 세계로 퍼져 나갔습니다. 오늘날 유럽의 많은 지역에서 헤모글로빈(Hb) 이상은 풍토병으로 분류되고 있습니다.
시장 역학
주요 시장 참여자들의 신제품 출시 증가와 인수합병(M&A) 활성화가 전 세계 헤모글로빈 질환 치료제 시장의 성장을 견인할 것으로 예측됩니다. 예를 들어, 2022년 8월 8일, 미국에 본사를 둔 다국적 제약·바이오기술 기업인 화이자(Pfizer Inc.)와, 마찬가지로 미국에 본사를 둔 헬스케어 기업인 세계 블러드 테라퓨틱스(Global Blood Therapeutics, Inc., GBT)는 화이자가 GBT를 인수하는 최종 합의를 체결했다고 발표했습니다. 이번 거래 조건에 따라 화이자는 월드·블러드·테라퓨틱스의 발행 주식 전부를 주당 68.50달러의 현금으로 인수합니다. 이에 따라 부채를 포함하고, 취득하는 현금을 차감한 총 기업 가치는 약 54억 달러가 됩니다. 양사의 이사회는 본 거래를 만장일치로 승인했습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장 성장 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 전 세계 헤모글로빈 질환 치료제 시장의 주요 기업 프로파일을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록했습니다.
- '세계 헤모글로빈 질환 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 헤모글로빈 질환 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 헤모글로빈병증 치료제 시장 : 약제 유형별(2021-2033년)
제5장 세계의 헤모글로빈병증 치료제 시장 : 질환 유형별(2021-2033년)
제6장 세계의 헤모글로빈병증 치료제 시장 : 유통 채널별(2021-2033년)
제7장 세계의 헤모글로빈병증 치료제 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
LSH 26.07.13Hemoglobinopathy Treatment Drugs Market is estimated to be valued at USD 5.74 Bn in 2026 and is expected to reach USD 10.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.74 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.60% | 2033 Value Projection: | USD 10.24 Bn |
The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). a and B thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE, and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. With approximately 7% of the worldwide population being carriers, hemoglobinopathies are the most common monogenic diseases and one of the world's major health problems. They were originally found mainly in the Mediterranean area and large parts of Asia and Africa. International migration has spread them from those areas all over the world. In many parts of Europe today, hemoglobin (Hb) defects are classified as endemic diseases.
Market Dynamics
Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global hemoglobinopathy treatment drugs market growth. For instance, on August 8, 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, and Global Blood Therapeutics, Inc., a U.S.-based Healthcare company, announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer Inc will acquire all the outstanding shares of Global Blood Therapeutics, Inc. for US$ 68.50 per share in cash, for a total enterprise value of approximately US$ 5.4 billion, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Prolong Pharmaceuticals, Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
- Global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy treatment drugs market
Detailed Segmentation:
- Global Hemoglobinopathy Treatment Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Analgesics
- Antibiotics
- ACE Inhibitors
- Hydroxyurea
- Others
- Global Hemoglobinopathy Treatment Drugs Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
- Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hemoglobinopathy Treatment Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Bristol-Myers Squibb Company
- GlycoMimetics Inc.
- Pfizer Inc.
- Anthera Pharmaceuticals Inc.
- Eli Lilly and Company
- Mast Therapeutics
- Daiichi Sankyo Company Ltd.
- Novartis International AG
- Bluebird Bio Inc.
- HemaQuest Pharmaceuticals Inc.
- Emmaus Medical Inc.
- Baxter International Inc.
- Prolong Pharmaceuticals
- Medunik USA Inc.
- Sangamo Therapeutics, Inc.
- Global Blood Therapeutics, Inc.
- Alnylam Pharmaceuticals
- Acceleron Pharma, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
5. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
6. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
7. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2021-2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
- North America
8. Competitive Landscape
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlycoMimetics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Anthera Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mast Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Daiichi Sankyo Company Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bluebird Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- HemaQuest Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Prolong Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Medunik USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Sangamo Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Global Blood Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
